Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: O- Medical and Surgical
Conditions
Interventions
Intervention1: Intravenous Lidocaine: given in dose of 2mg/kg bolus followed by maintenance 2mg/kg/hr infusion throughout surgery-
duration of drug infusion will be total duration of surgery
bolus w
Sponsors
AIIMS, Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: Female patients aged 18-70 years, American Society of Anaesthesiologists (ASA I-III) undergoing mastectomy for breast cancer
Exclusion criteria
Exclusion criteria: 1. Known allergy to lidocaine 2. Males 3. Age 70 years 4. ASA status IV or greater 5. History of previous breast surgery except diagnostic biopsy 6. Toilet mastectomy, Breast conservative surgery 7. BMI > 40 kg/m2 8. Kyphosis, scoliosis, previous spinal surgery 9. Infection at the injection site 10. Pregnancy 11. Patient refusal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of biomarkers predicting metastasis and recurrence in breast cancer patients undergoing total mastectomy â?? MMP2 ,MMP9 in patients receiving IV lidocaine and erector spinae blockTimepoint: preoperatively and 36 hours postoperatively samples shall be collected | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of immune markers- CD4, CD8, CD4/CD8 ratio 2. Comparison of intraoperative haemodynamics 3. Comparison of postoperative pain 4. Pain scores at 3 months 5. Comparison of quality of life at 3 months Timepoint: CD4, CD8- preoperative and 24 hours postoperative NRS-postoperative, 24 hours and 3 months Quality of life- 3 months postoperative | — |
Countries
India
Contacts
Public ContactDr Dhatri Jonna
AIIMS, Rishikesh
Outcome results
None listed